3 reports of this reaction
2.1% of all CAMPHOR, MENTHOL, METHYL SALICYLATE reports
#5 most reported adverse reaction
ERYTHEMA is the #5 most commonly reported adverse reaction for CAMPHOR, MENTHOL, METHYL SALICYLATE, manufactured by Hisamitsu America, Inc.. There are 3 FDA adverse event reports linking CAMPHOR, MENTHOL, METHYL SALICYLATE to ERYTHEMA. This represents approximately 2.1% of all 141 adverse event reports for this drug.
Patients taking CAMPHOR, MENTHOL, METHYL SALICYLATE who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is a less commonly reported adverse event for CAMPHOR, MENTHOL, METHYL SALICYLATE, but still significant enough to appear in the safety profile.
In addition to erythema, the following adverse reactions have been reported for CAMPHOR, MENTHOL, METHYL SALICYLATE:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 3 FDA reports for CAMPHOR, MENTHOL, METHYL SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 2.1% of all adverse event reports for CAMPHOR, MENTHOL, METHYL SALICYLATE, making it a notable side effect.
If you experience erythema while taking CAMPHOR, MENTHOL, METHYL SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.